Company News: Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015

Anergis, a company developing novel and proprietary ultra-fast allergy immunotherapeutics, will present three scientific posters at the 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015 (Barcelona, June 6-10, 2015). All posters will focus on Anergis´ birch pollen immunotherapeutic AllerT, featuring detailed clinical data as well as in vitro and in vivo safety and immunogenicity data. AllerT is Anergis´ most advanced product and based on the company´s proprietary Contiguous Overlapping Peptide (COP) platform.


The following scientific communications will be presented at the EAACI Conference 2015:

Presentation Title: “Phase IIb follow-up trial of sustained efficacy of AllerT allergy vaccine during a second birch pollen season”

Presenter: Gilles Della Corte

Time and Date: Sunday, June 7, 2015, at 02:06pm CET

Session: Oral Abstract Session OAS 10 AIT: Efficacy and clinical outcomes

Abstract #: 327


Presentation Title: Persistence of anti-Bet v 1 IgG4 prior and during a second pollen season after AllerT ultra-fast immunotherapy (phase IIb follow up)”

Presenter: Dr. Christophe Reymond

Time and Date: Tuesday, June 9, 2015, at 10:30am CET

Session: Poster Discussion Session PDS 25: Immunotherapy vaccines

Abstract #: 530


Presentation Title: “Requirement for aluminium hydroxide as adjuvant for successful ultra-fast immunotherapy with AllerT”

Presenter: Dr. Alexander Kettner

Time and Date: Monday, June 8, 2015, at 12:00pm CET

Session: Thematic Poster Session TPS 32: Allergen standardization

Abstract #: 1141